Circio joins collaboration to test the combination of TG01 vaccination with daratumumab and nivolumab in immunotherapy resistant patients with mutant RAS cancers
· Circio joins Georgetown University-sponsored phase 2 clinical trial to test TG01 mutant RAS cancer vaccine in combination with daratumumab from Janssen and nivolumab from BMS · The innovative combination will be tested in immunotherapy-resistant pancreatic and lung cancer and led by world-renowned immunotherapy expert Prof. Samir N. Khleif · The trial has been given approval to proceed by the US Food and Drug Administration (FDA), and will start enrolling patients by the end of 2023Oslo, Norway, 16 November 2023 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing